Advertisement

Current Hematologic Malignancy Reports

, Volume 11, Issue 3, pp 196–207 | Cite as

Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma

  • Vijaya Raj Bhatt
B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Armitage, Section Editor)
Part of the following topical collections:
  1. Topical Collection on B-cell NHL, T-cell NHL, and Hodgkin Lymphoma

Abstract

Observational studies indicate a similar or higher probability of disease control, higher risk of non-relapse mortality (NRM), and similar overall survival (OS) with allogeneic stem cell transplantation (alloSCT), compared to autologous SCT, in relapsed or refractory non-Hodgkin lymphoma. Careful patient selection and utilization of reduced intensity conditioning (RIC) alloSCT may allow reduction in NRM. The optimal conditioning regimen and the roles of radioimmunotherapy, T cell depletion, and tandem SCT continue to be explored. Recent studies highlight comparable results with haploidentical SCT and cord blood SCT, thus providing alternate donor sources. Disease relapse and late effects continue to be major problems. Optimization of SCT techniques (e.g., improved graft-versus-host disease prophylaxis), post-transplant monitoring of minimal residual disease, and post-transplant maintenance, or pre-emptive therapy (e.g., with novel therapies) are emerging strategies to reduce the risk of relapse. Survivorship management using a multidisciplinary care approach, adoption of healthy lifestyle, and socioeconomic counseling are integral parts of a high-quality transplant program.

Keywords

Non-Hodgkin lymphoma Diffuse large B cell lymphoma Follicular lymphoma Mantle cell lymphoma Peripheral T cell lymphoma Autologous stem cell transplantation Allogeneic stem cell transplantation 

Notes

Acknowledgments

This work was supported by the University of Nebraska Medical Center, College of Medicine, Physician-Scientist Training Program Grant 2015–2016.

Compliance with Ethical Standards

Conflict of Interest

The author declares that he has no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–61.CrossRefPubMedGoogle Scholar
  3. 3.
    Bhatt VR, Vose JM. Hematopoietic stem cell transplantation for non-Hodgkin lymphoma. Hematol Oncol Clin North Am. 2014;28(6):1073–95.CrossRefPubMedGoogle Scholar
  4. 4.
    Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013;31(12):1506–13.CrossRefPubMedGoogle Scholar
  5. 5.
    Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725–32.CrossRefPubMedGoogle Scholar
  6. 6.
    Armitage JO, Bociek RG. Increasing complexity of high-grade B-cell lymphomas. Cancer. 2014;120(11):1611–3.CrossRefPubMedGoogle Scholar
  7. 7.
    Armitage JO. How I, treat patients with diffuse large B-cell lymphoma. Blood. 2007;110(1):29–36.CrossRefPubMedGoogle Scholar
  8. 8.
    Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin BM, Ataergin AS, Bitran JD, et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant. 2010;16(1):35–45.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    van Besien K, Loberiza Jr FR, Bajorunaite R, Armitage JO, Bashey A, Burns LJ, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102(10):3521–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Ganti AK, Bierman PJ, Lynch JC, Bociek RG, Vose JM, Armitage JO. Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol. 2005;16(4):618–24.CrossRefPubMedGoogle Scholar
  11. 11.
    Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013;31(25):3100–9.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM, et al. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. Biol Blood Marrow Transplant. 2011;17(7):1051–7.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.•
    Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol. 2014;32(4):273–81. This large retrospective study compares the results of autologous and reduced intensity conditioning allogeneic transplantation for chemotherapy-sensitive mantle cell lymphoma. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ghobadi A, Nolley E, Liu J, McBride A, Stockerl-Goldstein K, Cashen A. Retrospective comparison of allogeneic vs autologous transplantation for diffuse large B-cell lymphoma with early relapse or primary induction failure. Bone Marrow Transplant. 2015;50(1):134–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Bhatt VR, Loberiza Jr FR, Jing H, Bociek RG, Bierman PJ, Maness LJ, et al. Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades. Clin Lymphoma Myeloma Leuk. 2015;15(7):409–15.CrossRefPubMedGoogle Scholar
  16. 16.
    Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–9.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Sorror M, Storer B, Gopal A, Holmberg L, Sandmaier BM, Bensinger WI, et al. Comorbidity, lactate dehydrogenase (LDH), and chemosensitivity are independent predictors of mortality after autologous hematopoietic cell transplantation (HCT) for patients (pts) with lymphoma. ASH Annual Meeting Abstract. 2007;110(11):616.Google Scholar
  18. 18.
    Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN, et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant. 2008;14(2):236–45.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Muffly LS, Boulukos M, Swanson K, Kocherginsky M, Cerro PD, Schroeder L, et al. Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. Biol Blood Marrow Transplant. 2013;19(3):429–34.CrossRefPubMedGoogle Scholar
  20. 20.
    Holmes HM, Des Bordes JK, Kebriaei P, Yennu S, Champlin RE, Giralt S, et al. Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates. J Geriatr Oncol. 2014;5(4):422–30.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014;99(8):1373–9.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR, et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012;120(20):4256–62.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.•
    Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2013;19(4):625–31. This large retrospective study compares the results of myeloablative versus non-myeloablative/reduced intensity conditioning allogeneic transplantation for refractory mantle cell lymphoma. CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.•
    Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, et al. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant. 2013;19(5):746–53. This large retrospective study compares the results of myeloablative versus non-myeloablative/reduced intensity conditioning allogeneic transplantation for refractory diffuse large B cell lymphoma and grade III follicular lymphoma. CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Rodriguez R, Nademanee A, Ruel N, Smith E, Krishnan A, Popplewell L, et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006;12(12):1326–34.CrossRefPubMedGoogle Scholar
  26. 26.
    Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, et al. Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: results from cancer and leukemia group B 100103 (alliance for clinical trials in oncology)/blood and marrow transplant clinical trial network 0502. J Clin Oncol. 2015.Google Scholar
  27. 27.
    Kasamon YL, Bolanos-Meade J, Prince GT, Tsai HL, McCurdy SR, Kanakry JA, et al. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol. 2015;33(28):3152–61.CrossRefPubMedGoogle Scholar
  28. 28.
    Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124(3):344–53.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Akhtari M, Bhatt VR, Tandra PK, Krishnamurthy J, Horstman H, Dreessen A, et al. Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients. Cancer Biol Ther. 2013;14(12):1077–88.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin’s lymphoma patients. J Clin Oncol. 2003;21(5):897–906.CrossRefPubMedGoogle Scholar
  31. 31.
    Litzow MR, Perez WS, Klein JP, Bolwell BJ, Camitta B, Copelan EA, et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol. 2002;119(4):1115–24.CrossRefPubMedGoogle Scholar
  32. 32.
    Hartman AR, Williams SF, Dillon JJ. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant. 1998;22(5):439–43.CrossRefPubMedGoogle Scholar
  33. 33.
    Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen—a report from the acute leukemia working party of the European group for blood and marrow transplantation. J Clin Oncol. 2013;31(28):3549–56.CrossRefPubMedGoogle Scholar
  34. 34.
    Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013;122(24):3863–70.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Bredeson C, LeRademacher J, Kato K, Dipersio JF, Agura E, Devine SM, et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood. 2013;122(24):3871–8.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Lee JH, Joo YD, Kim H, Ryoo HM, Kim MK, Lee GW, et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol. 2013;31(6):701–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Liu H, Zhai X, Song Z, Sun J, Xiao Y, Nie D, et al. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. J Hematol Oncol. 2013;6:15.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Rambaldi A, Grassi A, Masciulli A, Boschini C, Mico MC, Busca A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015;16(15):1525–36.CrossRefPubMedGoogle Scholar
  39. 39.
    Gopal AK, Gooley TA, Rajendran JG, Pagel JM, Fisher DR, Maloney DG, et al. Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma. Biol Blood Marrow Transplant. 2014;20(6):770–5.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, et al. Phase III randomized intergroup trial of CHOP Plus rituximab compared with CHOP chemotherapy plus 131iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol. 2013;31(3):314–20.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Scholz CW, Pinto A, Linkesch W, Lindén O, Viardot A, Keller U, et al. 90Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol. 2013;31(3):308–13.CrossRefPubMedGoogle Scholar
  42. 42.
    Decaudin D, Mounier N, Tilly H, Ribrag V, Ghesquieres H, Bouabdallah K, et al. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study. Clin Lymphoma Myeloma Leuk. 2011;11(2):212–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Rand A, et al. Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2008;41(4):355–61.CrossRefPubMedGoogle Scholar
  44. 44.
    Bethge WA, Lange T, Meisner C, von Harsdorf S, Bornhaeuser M, Federmann B, et al. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. Blood. 2010;116(10):1795–802.CrossRefPubMedGoogle Scholar
  45. 45.
    Abou-Nassar KE, Stevenson KE, Antin JH, McDermott K, Ho VT, Cutler CS, et al. (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma. Bone Marrow Transplant. 2011;46(12):1503–9.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, et al. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood. 2012;119(26):6373–8.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Vose JM, Bierman PJ, Loberiza FR, Enke C, Hankins J, Bociek RG, et al. Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2013;19(1):123–8.CrossRefPubMedGoogle Scholar
  48. 48.
    Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23(3):461–7.CrossRefPubMedGoogle Scholar
  49. 49.
    Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96(9):2934–42.PubMedGoogle Scholar
  50. 50.
    Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol. 2013;31(13):1662–8.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood. 2001;98(12):3192–204.CrossRefPubMedGoogle Scholar
  52. 52.
    Delgado J, Canals C, Attal M, Thomson K, Campos A, Martino R, et al. The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphoma. Leukemia. 2011;25(3):551–5.CrossRefPubMedGoogle Scholar
  53. 53.
    Thomson KJ, Morris EC, Milligan D, Parker AN, Hunter AE, Cook G, et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol. 2010;28(23):3695–700.CrossRefPubMedGoogle Scholar
  54. 54.
    Ingram W, Devereux S, Das-Gupta EP, Russell NH, Haynes AP, Byrne JL, et al. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Br J Haematol. 2008;141(2):235–43.CrossRefPubMedGoogle Scholar
  55. 55.
    Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS, et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood. 2004;104(12):3797–803.CrossRefPubMedGoogle Scholar
  56. 56.
    van Kampen RJ, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin’s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol. 2011;29(10):1342–8.CrossRefPubMedGoogle Scholar
  57. 57.
    Rezvani AR, Kanate AS, Efron B, Chhabra S, Kohrt HE, Shizuru JA, et al. Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning. Bone Marrow Transplant. 2015;50(10):1286–92.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Cohen S, Kiss T, Lachance S, Roy DC, Sauvageau G, Busque L, et al. Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity. Biol Blood Marrow Transplant. 2012;18(6):951–7.CrossRefPubMedGoogle Scholar
  59. 59.•
    Chen YB, Li S, Fisher DC, Driscoll J, Del Rio C, Abramson J, et al. Phase II trial of tandem high-dose chemotherapy with autologous stem cell transplantation followed by reduced-intensity allogeneic stem cell transplantation for patients with high-risk lymphoma. Biol Blood Marrow Transplant. 2015;21(9):1583–8. This phase II trial demonstrates promising results with tandem transplant strategy in high-risk lymphoma. CrossRefPubMedGoogle Scholar
  60. 60.
    Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033–40.CrossRefPubMedGoogle Scholar
  61. 61.
    Gaballa S, Palmisiano N, Alpdogan O, Carabasi M, Filicko-O’Hara J, Kasner M, et al. A two-step haploidentical versus a two-step matched related allogeneic myeloablative peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(1):141–8.CrossRefPubMedGoogle Scholar
  62. 62.
    Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, et al. Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Biol Blood Marrow Transplant. 2015;21(7):1299–307.CrossRefPubMedGoogle Scholar
  63. 63.
    Rodrigues CA, Sanz G, Brunstein CG, Sanz J, Wagner JE, Renaud M, et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2009;27(2):256–63.CrossRefPubMedGoogle Scholar
  64. 64.
    Roberto C, Sabine F, Stefania B, Barbara S, Angela G, Catherine F, et al. Comparison of umbilical cord blood and haploidentical donor grafts in adults with high risk hematologic diseases after fludarabine cyclophosphamide and TBI 2 Gy based reduced-intensity conditioning regimen stem cell transplantation. Blood. 2013;122(21):3288.Google Scholar
  65. 65.
    Horan JT, Logan BR, Agovi-Johnson MA, Lazarus HM, Bacigalupo AA, Ballen KK, et al. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? J Clin Oncol. 2011;29(7):805–13.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487–96.CrossRefPubMedGoogle Scholar
  67. 67.
    McCurdy SR, Kanakry JA, Showel MM, Tsai H-L, Bolaños-Meade J, Rosner GL, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015;125(19):3024–31.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Al-Homsi AS, Roy TS, Cole K, Feng Y, Duffner U. Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21(4):604–11.CrossRefPubMedGoogle Scholar
  69. 69.
    Reshef R, Huffman AP, Gao A, Luskin MR, Frey NV, Gill SI, et al. High graft CD8 cell dose predicts improved survival and enables better donor selection in allogeneic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2015;33(21):2392–8.CrossRefPubMedGoogle Scholar
  70. 70.
    Ferro RA, Bhatt VR, Smith L, Lunning MA, Bierman PJ, Armitage JO, Bociek G, Vose J Long-term outcomes of rituximab use prior to autologous stem cell transplant (ASCT) in low-grade follicular lymphoma (FL) at the time of first progression ASCO 2015 Annual Meeting May 29-June 2, 2015 ChicagoGoogle Scholar
  71. 71.
    Vose JM, Bierman PJ, Loberiza FR, Lynch JC, Bociek GR, Weisenburger DD, et al. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and follicular international prognostic index. Biol Blood Marrow Transplant. 2008;14(1):36–42.CrossRefPubMedGoogle Scholar
  72. 72.
    Nademanee A, Palmer JM, Popplewell L, Tsai NC, Delioukina M, Gaal K, et al. High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors. Biol Blood Marrow Transplant. 2011;17(10):1481–9.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K, et al. Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2010;16(10):1419–27.CrossRefPubMedGoogle Scholar
  74. 74.
    Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27(1):106–13.CrossRefPubMedGoogle Scholar
  75. 75.
    Arcaini L, Montanari F, Alessandrino EP, Tucci A, Brusamolino E, Gargantini L, et al. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Ann Oncol. 2008;19(7):1331–5.CrossRefPubMedGoogle Scholar
  76. 76.
    Morschhauser F, Recher C, Milpied N, Gressin R, Salles G, Brice P, et al. A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. Ann Oncol. 2012;23(10):2687–95.CrossRefPubMedGoogle Scholar
  77. 77.
    Hicks LK, Woods A, Buckstein R, Mangel J, Pennell N, Zhang L, et al. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant. 2009;43(9):701–8.CrossRefPubMedGoogle Scholar
  78. 78.
    Brugger W, Hirsch J, Grunebach F, Repp R, Brossart P, Vogel W, et al. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol. 2004;15(11):1691–8.CrossRefPubMedGoogle Scholar
  79. 79.
    Chen YB, Li S, Lane AA, Connolly C, Del Rio C, Valles B, et al. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant. 2014;20(12):2042–8.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Antar A, Kharfan-Dabaja MA, Mahfouz R, Bazarbachi A. Sorafenib maintenance appears safe and improves clinical outcomes in FLT3-ITD acute myeloid leukemia after allogeneic hematopoietic cell transplantation. Clin Lymphoma Myeloma Leuk. 2015;15(5):298–302.CrossRefPubMedGoogle Scholar
  81. 81.•
    Glass B, Hasenkamp J, Wulf G, Dreger P, Pfreundschuh M, Gramatzki M, et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol. 2014;15(7):757–66. This phase II trial demonstrates a lack of survival benefit with rituximab maintenance after allogeneic transplantation in NHL; many patients were previously exposed to rituximab. CrossRefPubMedGoogle Scholar
  82. 82.
    Chen R, Palmer JM, Tsai NC, Thomas SH, Siddiqi T, Popplewell L, et al. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014;20(11):1864–8.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922–6.CrossRefPubMedGoogle Scholar
  84. 84.
    Sehn LH, Chua NS, Mayer J, Dueck GS, et al. GADOLIN: primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. ASCO Meet Abstr. 2015;33(15_suppl):LBA8502. Trn, #x011B.Google Scholar
  85. 85.
    Salles GA, Schuster SJ, De Vos S, Wagner-Johnston ND, Viardot A, Flowers C, et al. Idelalisib efficacy and safety in follicular lymphoma patients from a phase 2 study. ASCO Meet Abstr. 2015;33(15_suppl):8529.Google Scholar
  86. 86.
    Davids MS, Seymour JF, Gerecitano JF, Kahl BS, Pagel JM, Wierda WG, et al. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. ASCO Meet Abstr. 2014;32(15_suppl):8522.Google Scholar
  87. 87.
    Advani RH, Flinn I, Sharman JP, Magid Diefenbach CS, Kolibaba KS, Press OW, et al. Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): durable responses at lower dose level. ASCO Meet Abstr. 2015;33(15_suppl):8503.Google Scholar
  88. 88.
    Kimby E, Martinelli G, Ostenstad B, Mey UJ, Rauch D, Wahlin BE, et al. Rituximab plus lenalidomide improves the complete remission rate in comparison with rituximab monotherapy in untreated follicular lymphoma patients in need of therapy. Primary endpoint analysis of the randomized phase-2 trial SAKK 35/10. Blood. 2014;124(21):799.Google Scholar
  89. 89.
    Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood. 2014;124(21):291.Google Scholar
  90. 90.
    Kochenderfer JN, Dudley ME, Kassim SH, Somerville RPT, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540–9.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Savani BN, Griffith ML, Jagasia S, Lee SJ. How I treat late effects in adults after allogeneic stem cell transplantation. Blood. 2011;117(11):3002–9.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Burns LJ. Late effects after autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009;15(1 Suppl):21–4.CrossRefPubMedGoogle Scholar
  93. 93.
    Hill BT, Rybicki L, Bolwell BJ, Smith S, Dean R, Kalaycio M, et al. The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls. Br J Haematol. 2011;152(5):561–9.CrossRefPubMedGoogle Scholar
  94. 94.
    Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(3):348–71.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Internal Medicine, Division of Hematology-OncologyUniversity of Nebraska Medical CenterOmahaUSA

Personalised recommendations